Prospective Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial

Diokno, Ananias C.; Appell, Rodney A.; Sand, Peter K.; Dmochowski, Roger R.; Gburek, Bernard M.; Klimberg, Ira W.; Kell, Sherron H.
June 2003
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p687
Academic Journal
• Objective: To compare the efficacy and tolerability of extended-release formulations of oxybutynin chloride and tolterodine tartrate in women with overactive bladder. • Patients and Methods: The OPERA (Overactive bladder: Performance of Extended Release Agents) trial was a randomized, double-blind, active-control study performed at 71 US study centers from November 21, 2000, to October 18, 2001. Extended-release formulations of oxybutynin at 10 mg/d or tolterodine at 4 mg/d were given for 12 weeks to women with 21 to 60 urge urinary incontinence (UUI) episodes per week and an average of 10 or more voids per 24 hours. Episodes of UUI (primary end point), total (urge and non-urge) incontinence, and micturition were recorded in 24-hour urinary diaries at baseline and at weeks 2, 4, 8, and 12 and compared. Adverse events were also evaluated. • Results: Improvements in weekly UUI episodes were similar for the 790 women who received extended-release formulations of oxybutynin (n=391) or tolterodine (n=399). Oxybutynin was significantly more effective than tolterodine in reducing micturition frequency (P=.003), and 23.0% of women taking oxybutynin reported no episodes of urinary incontinence compared with 16.8% of women taking tolterodine (P=.03). Dry mouth, usually mild, was more common with oxybutynin (P=.02). Adverse events were generally mild and occurred at low rates, with both groups having similar discontinuation of treatment due to adverse events. • Conclusions: Reductions in weekly UUI and total incontinence episodes were similar with extended-release formulations of oxybutynin and tolterodine. In the oxybutynin group, micturition frequency was significantly lower, and the percentage of women reporting no urinary incontinence episodes was significantly higher compared with the tolterodine group. Dry mouth was more common with oxybutynin, but tolerability was otherwise comparable, including adverse events involving the central nervous system.


Related Articles

  • Which oral therapy warranted in urge urinary incontinence?  // PharmacoEconomics & Outcomes News;1/15/2005, Issue 469, p12 

    Presents information on the different oral therapies for treating urge urinary incontinence. Types of oral medication evaluated; Problems found in several of the treatments; Comparison between the annual costs of the therapies.

  • Advances in Medical Management of Overactive Bladder. Richelson, Elliott; Elliott, Daniel S. // Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p681 

    Editorial. Discusses advances in the medical management of overactive bladder or urinary incontinence. Oral extended-release forms of two different muscarinic receptor antagonists, oxybutynin and tolterodine; Introduction of the transdermal oxybutynin patch; Pharmacokinetic difference between...

  • Long-term effects of injections of collagen into the urethral submucosa for the treatment of incontinence in bitches.  // Veterinary Record: Journal of the British Veterinary Association;4/2/2005, Vol. 156 Issue 14, p437 

    Examines the long-term effects of injections of collagen into the urethral submucosa for the treatment of incontinence in bitches. Duration of the follow up on bitches; Improvement seen in dogs which had received additional treatment with alpha-adrenergic agonists; Development of mild,...

  • Oxybutynin Topical.  // AHFS Consumer Medication Information;Jun2017, p1 

    Oxybutynin topical gel is used to control frequent urination, urgent need to urinate, and urge urinary incontinence (sudden strong need to urinate that may cause urine leakage) in people who have overactive bladder (OAB; condition in which the bladder muscles tighten uncontrollably to empty the...

  • Better continence with diversions.  // Urology Times;Jan95, Vol. 23 Issue 1, p19 

    Reports that the key to better continence with Mitrofanoff valves for urinary diversion seems to be the length of the conduit. Better performance of appendiceal conduits due to longer profile and higher closure pressures.

  • Product helps treat male incontinence.  // Urology Times;Feb95, Vol. 23 Issue 2, p22 

    Presents the Condom Seal, a product for the treatment of male incontinence. Benefits of the product; Contact information.

  • Incontinence: Cross your legs.  // Consumer Reports on Health;Oct95, Vol. 7 Issue 10, p113 

    Suggests that women with stress urinary incontinence can reduce their problem by crossing their legs whenever the situation arises according to the November 1994 issue of `Obstetrics & Gynecology'.

  • Update on a computerized approach to incontinence management. Menard, Cecile; Crooks, Valerie // Nursing Homes: Long Term Care Management;Jan/Feb94, Vol. 43 Issue 1, p38 

    Presents a training and management program for urinary incontinence based on computerized information. Change in training goals for urinary incontinence management; Phases of program development. INSET: Other applications coming..

  • UNMENTIONABLE BUT NOT UNTREATABLE. Krucoff, Carol // Saturday Evening Post;Sep/Oct99, Vol. 271 Issue 5, p26 

    Offers a look at urinary incontinence. People prone to experience urinary incontinence; How to treat urinary incontinence; Exercises; Behavioral treatment; Factors predisposing a person to urinary incontinence. INSET: Resources.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics